Acquisitions

AddLife continuously seeks companies to acquire and is in ongoing dialogue with several potential acquisition targets in Europe. In 2025, three acquisitions were completed, of which two in the Medtech business area and one in the Labtech business area.

AddLife’s acquisition strategy
AddLife’s acquisition strategy aims to strengthen the Group’s position in selected, profitable niches over the long term through entrepreneur-driven companies with a clear market position. The strategy can be summarised in three main tracks:

• The subsidiaries can make small bolt-on acquisitions to strengthen existing businesses in their niches, for example through complementary product portfolios, geographical reinforcement or increased service capacity.
• The business areas can expand and build market and/or product positions in selected segments where AddLife already has an established presence and sees good opportunities to gain further market share.
• The business areas can add new, adjacent market segments in areas where AddLife assesses that there are conditions to achieve a leading position, both in terms of offering and profitability.

Acquisitions completed in 2025

• On April 1, 2025, AddLife acquired all shares in Edge Medical Ltd., which has been added to the Medtech business area. Edge Medical is a leading UK distributor in orthopaedic surgery, spinal surgery and neurology with operations in England and Ireland. The company has annual sales of approximately GBP 8 million (about SEK 90 million) and around 20 employees. The acquisition strengthens AddLife’s position in advanced surgery, broadens the offering towards larger hospital customers and creates a platform for further expansion in the UK and Irish markets.
• On December 1, 2025, Pharmacold A/S in Denmark was acquired and added to the Labtech business area. Pharmacold specialises in refrigeration technology and service for the pharmaceutical and healthcare sectors, with annual sales of approximately EUR 3.4 million (about SEK 38 million) and around 20 employees. The company complements Labtech’s offering in customer-specific temperature-sensitive handling of pharmaceuticals and samples, an area with increasing regulatory requirements and growing demand.
• On the same day, December 1, 2025, Opitek International ApS in Denmark was also acquired and added to the Medtech business area. Opitek is a niche manufacturer specialised in patient positioning for surgery, with annual sales of approximately DKK 8 million (about SEK 12 million) and 2 employees. The acquisition strengthens Medtech’s portfolio in orthopaedics and advanced surgical products and provides increased control over the value chain through proprietary, differentiated products.

All of the acquisitions are fully in line with AddLife’s strategy to acquire small and medium-sized entrepreneur-driven companies in defined, fast-growing and profitable segments.